Joel Beatty

Stock Analyst at Baird

(4.52)
# 297
Out of 5,017 analysts
199
Total ratings
49.38%
Success rate
30.07%
Average return

Stocks Rated by Joel Beatty

Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10$7
Current: $4.25
Upside: +64.71%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50$67
Current: $34.41
Upside: +94.71%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4$6
Current: $3.56
Upside: +68.54%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7$9
Current: $16.20
Upside: -44.44%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110$145
Current: $132.69
Upside: +9.28%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28$31
Current: $20.06
Upside: +54.54%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38$24
Current: $31.62
Upside: -24.10%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $799.56
Upside: -14.95%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30$29
Current: $14.98
Upside: +93.59%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70$66
Current: $66.06
Upside: -0.09%
Maintains: Outperform
Price Target: $167$155
Current: $135.14
Upside: +14.70%
Maintains: Outperform
Price Target: $160$162
Current: $121.15
Upside: +33.72%
Maintains: Outperform
Price Target: $38$41
Current: $32.17
Upside: +27.45%
Maintains: Outperform
Price Target: $27$16
Current: $12.25
Upside: +30.61%
Maintains: Outperform
Price Target: $32$16
Current: $11.87
Upside: +34.79%
Maintains: Outperform
Price Target: $117$73
Current: $52.34
Upside: +39.47%
Maintains: Outperform
Price Target: $28$32
Current: $20.40
Upside: +56.86%
Initiates: Outperform
Price Target: $75
Current: $64.97
Upside: +15.44%
Upgrades: Outperform
Price Target: $3$11
Current: $14.12
Upside: -22.10%
Maintains: Outperform
Price Target: $6$7
Current: $1.99
Upside: +251.76%
Maintains: Neutral
Price Target: $72$65
Current: $52.45
Upside: +23.93%
Maintains: Outperform
Price Target: $68$72
Current: $32.02
Upside: +124.86%
Maintains: Outperform
Price Target: $540$240
Current: $1.63
Upside: +14,623.93%
Downgrades: Neutral
Price Target: $4.5
Current: $1.27
Upside: +254.33%
Maintains: Outperform
Price Target: $24$25
Current: $9.72
Upside: +157.20%
Maintains: Outperform
Price Target: $11$9
Current: $0.60
Upside: +1,392.29%
Maintains: Outperform
Price Target: $32$28
Current: $15.20
Upside: +84.21%
Initiates: Outperform
Price Target: $16
Current: $1.83
Upside: +774.32%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.71
Upside: -26.90%
Initiates: Outperform
Price Target: $44
Current: $1.49
Upside: +2,853.02%
Maintains: Outperform
Price Target: $60$58
Current: $36.25
Upside: +60.00%
Maintains: Outperform
Price Target: $18$24
Current: $26.77
Upside: -10.35%
Downgrades: Underperform
Price Target: $18
Current: $19.39
Upside: -7.17%
Maintains: Outperform
Price Target: $9$6
Current: $2.26
Upside: +165.49%
Upgrades: Neutral
Price Target: $36$28
Current: $5.86
Upside: +377.82%
Downgrades: Neutral
Price Target: $170$175
Current: $464.95
Upside: -62.36%
Downgrades: Neutral
Price Target: $14
Current: $5.23
Upside: +167.69%
Downgrades: Neutral
Price Target: $108
Current: $21.96
Upside: +391.80%
Maintains: Buy
Price Target: $80$78
Current: $70.59
Upside: +10.50%
Maintains: Buy
Price Target: $140$100
Current: $16.43
Upside: +508.83%
Maintains: Buy
Price Target: $480$120
Current: $19.17
Upside: +525.98%
Maintains: Buy
Price Target: $480$450
Current: $3.06
Upside: +14,605.88%
Upgrades: Buy
Price Target: n/a
Current: $2.72
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $8.62
Upside: +74.01%
Maintains: Neutral
Price Target: $240$120
Current: $0.62
Upside: +19,339.49%
Maintains: Buy
Price Target: $15$19
Current: $9.93
Upside: +91.34%